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Abstract
Intracranial aneurysms are a common vascular abnormality identified incidentally
or after rupture leading to aneurysmal subarachnoid hemorrhage. However, accurately
assessing the risk of aneurysmal disease progression is challenging. Here we propose
a prospective cohort study to identify if elevated levels of matrix metalloproteinase-9, a
molecular marker of vascular degeneration, in the peripheral blood samples of subjects
with unruptured intracranial aneurysms correlate with aneurysm progression over a
follow up period. This study aims to aid in identifying patients at increased risk of
aneurysm progression in order to guide treatment decisions and ultimately decrease
subarachnoid hemorrhage morbidity and mortality.

vi

CHAPTER 1 - INTRODUCTION
1.1 - Overview of Aneurysmal Epidemiology, Significance, and Detection
Intracranial aneurysms (IAs) are acquired pathological expansions of the
intracranial vasculature often presenting in adulthood as nontraumatic or aneurysmal
subarachnoid hemorrhage (aSAH) secondary to aneurysmal rupture. It is estimated that
between 3% and 6% of the United States population over the age of 30 harbors an IA
with this incidence increasing with age.1, 2, 3, 4, 5, 6 One quarter of these individuals have
multiple IAs.7 Several IA subtypes exist based on their morphology to include saccular,
fusiform, and dissecting forms.8 Between 80%-90% of all IAs are saccular, also known
as berry aneurysms, due to their rounded appearance.7 Saccular IAs are characterized
by their thin or absent tunica media and internal elastic lamina and are found largely at
arterial bifurcations near the circle of Willis at the base of the brain.9,10,11
aSAH secondary to rupture poses the most serious health effect of IAs, occurring
with an estimated incidence of 30,000 per year in North America. 12 While most IAs do
not progress to rupture, rupture carries with it a significant health burden. Despite
advances in treatment, fatality is approximately 45% one month after rupture. 13 Greater
than 40% of aSAH survivors never return to pre-morbid capabilities.14 Of these, 10% 20% are unable to function independently.15 Identification of IAs prior to rupture is thus
important, considering the high morbidity and mortality associated with aSAH.
IA detection is performed using magnetic resonance angiography (MRA),
computed tomographic angiography (CTA), or invasive angiography. Despite the large
number of people harboring IAs, approximately 50% of these aneurysms are found only
after rupture.16 Of the remaining 50% of IAs found prior to aSAH, small IAs measuring <
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7mm are often asymptomatic and thus found incidentally. Larger IAs, accounting for
15% of all IAs, are more likely to cause symptoms leading to identification such as
headaches, seizures, motor or sensory changes, or third nerve palsy. 17
Screening via CTA or MRA is recommended in patients seen to be at increased
risk of IA formation or rupture such as those with ≥2 family members with IA or SAH,
conditions such as Polycystic Kidney Disease, Marfan’s syndrome, type IV EhlersDanlos syndrome, neurofibromatosis type 1, alpha-1-antitrypsin deficiency,
fibromuscular dysplasia, pheochromocytoma, and Klinefelter's syndrome, as well as
congenital malformations such as coarctation of the aorta, bicuspid aortic valve, and
intracranial arteriovenous malformations, as these patients generally follow a distinctly
different treatment course and present at earlier ages.18

1.2: Treatment Options and Associated Risks
Treatment of identified IAs is accomplished in one of two ways, either via surgical
intervention or observation. Both carry health risks as intervention carries the risk of
invasive complications while observation places the patient at risk of aSAH.
Surgical treatment is generally accomplished either by open craniotomy with
vascular clipping or endovascular coil embolization. Both surgical treatments are
associated with non-trivial chances of complications. One large prospective cohort
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demonstrated that clipping was associated with a severe functional disability of 17.5%
at 30 days post-op and a 2.3% chance of death at post-op day 30.19 These percentages
increase in patients older than 50 years old.18, 20 Craniotomy with clipping, as a more
invasive treatment than endovascular coiling, is associated with more disability
immediately after the procedure, most of which resolve over time.21 Despite this, one
large review reported a 13.7% chance of morbidity in clipping vs a 4.0% associated with
coiling, with risk increasing with age. As such Endovascular coiling is generally seen as
safer and is performed more commonly.20 However, coiling is still associated with
thromboembolic events, intraoperative IA rupture, and a greater need for re-intervention
due to coil compaction.21

1.3 - Risk of Disease Progression
One of the main challenges in IA management is determining which IAs are at an
increased risk of rupture and thus require intervention. IAs have a 0.95% risk of rupture
per year according to a large prospective cohort of Japanese descent. 22 This risk has
been found to be as high as 1.4% per year in a recent systematic review. 23 Physically,
rupture is dependent on the interaction between wall tension versus wall strength as
described by Laplace’s Law which states that vascular wall tension increases as a
function of vessel size, intravascular pressure, and wall thinness.7, 24, 25, 26 The risk of
SAH associated with IA rupture has thus historically been understood as a function of IA
size, where larger IAs are more prone to rupture.22, 27 Multiple studies have
demonstrated higher overall risk for IA rupture in IAs >7mm.7, 22, 28 However, size alone
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is insufficient to accurately assess IA rupture risk as it is common for IAs under 7mm to
rupture.29 A more detailed discussion of IA rupture covariates is included in Chapter 2.

1.4 - Treatment Guidelines
Treatment decisions regarding IAs require careful weighing of the risk of rupture
against the risk of surgical complications in the setting of age.7 However, guidelines rely
on expert opinion in the context of IA natural history. Nevertheless, these guidelines
recommend that surgical treatment be advocated in patients with symptomatic or large
IAs, especially in younger patients or IAs in the posterior circulation, as the risk of
rupture is seen to outweigh the risks of intervention.19, 27, 30, 31, 32 Because risk of aSAH
increases with IA size while risk of surgical complications increases with age, guidelines
recommend that surgical treatment is appropriate in patients under 60 with IAs > 7mm,
preferably via endovascular coiling to reduce complication risks.19 In patients over 60,
intervention is usually recommended in IAs >12mm.
Conservative management via observation is advocated in asymptomatic IAs
<7mm, and is composed of serial imaging with aggressive control of modifiable risk
factors for aSAH such as reduction in smoking ,alcohol, and blood pressure. 5 The
American Heart Association suggests that a follow up image at 6-12 months after
discovery followed by a 12-24 month follow up image is reasonable.18 Other sources
recommend reimaging of small aneurysms every six months as they may be at higher
risk of progression.7 IAs measuring 7-10mm need to take into account the patient's age
and comorbidities.33 Despite these guidelines, conservative management retains a risk
of sudden IA rupture. Further, assessment for IA growth requires expensive imaging
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tests, highlighting the need for timely and cost-effective alternatives to assess for
disease progression. Understanding the role inflammation plays in the disease
progression may aid in these tasks.

1.5 - Aneurysmal Histology and Development
Arterial walls are composed of 3 layers from innermost to outermost. The
innermost layer, the tunica intima, is composed of an endothelial cell layer, a
subendothelium composed of the extracellular matrix proteins collagen, elastin, and
ground substance. The internal elastic lamina composed of collagens and elastins.34
The Tunica media is composed of vascular smooth muscle cells (VSMCs) and the
external elastic lamina composed of elastin and collagen fibers. Elastin fibers stretch
while collagen fibers provide rigid support with little ability to stretch prior to failure. The
outermost layer is the tunica externa composed of collagen fibers, fibroblasts, and the
vasa vasorum. Additionally, while the tunica media contains an external elastic lamina in
most arteries throughout the body, the cerebral vasculature does not contain this
additional elastic layer.34 The lack of an external elastic lamina in cerebral arteries lends
them more prone to aneurysm formation as the elastic lamina and collagen fibers
provide resistance to stretch related deformation and structural strength respectively.24,
35

Histological examinations of IA reveal several pathological changes in these
three arterial layers.36 The most widely observed is the loss of the internal elastic lamina
and atrophy of the tunica media is considered a hallmark of the disease and forces the
remaining collagen fibers of the tunica externa to maintain the bulk of aneurysmal
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structural integrity.3, 9, 24, 36, 37 These findings are often found in the presence of fibrotic
changes and infiltration of leukocytes into the remaining arterial wall. Leukocytes within
IA walls secrete inflammatory chemoattractants and enzymes such as matrix
metalloproteinases (MMPs)which are known to degrade the arterial wall components. 38,
39

These histological changes are caused by pathologic blood flow near arterial
bifurcations which expose vascular endothelial cells to two increased wall stresses. 40
The first is cyclic transmural stress caused by arterial pulsations related to blood
pressure, the other is wall shear stress, a frictional force generated as blood flows past
the arterial wall through the vessel lumen. Increases in either, through hypertension or
via non laminar flow at arterial bifurcations and curvatures, is noxious to endothelial
cells and causes the release of inflammatory adhesion molecules, reactive oxygen
species, and complement system activation.3, 7, 39 This endothelial damage and its
resulting inflammatory response begins a process of vascular remodeling. 8
The remodeling process requires a balance between cell proliferation, cell
apoptosis, and extracellular matrix reconstruction via a variety of factors, enzymes, and
second messengers.39, 41, 42 In IA development, tissue breakdown outpaces tissue
construction as leukocyte infiltration leads to VSMC apoptosis and progressive tunica
media thinning.39 Leukocytes secrete proteases such as (MMPs) that act to both
breakdown extracellular matrix proteins such as collagen and elastin and induce further
macrophage infiltration.3,24 The degradation of arterial wall layers is believed to be
catalyzed by these increased MMPs.43 Loss of the internal elastic lamina, ECM, and
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VSMC layer results in weakening of the vascular wall, allowing for pathologic bulging of
the IA under arterial pressure.

1.6 - Overview of Matrix Metalloproteinases
MMPs are a family of peptidases containing a zinc ion catalytic domain. 57 MMPs
are expressed intra or extracellularly in their inactive form and require activation to
begin cleavage of their respective substrates.44 Currently there are over 28 individual
MMPs grouped into six families according to their main substrates although a large
amount of overlap between families exists.45, 46 Several inhibitors of MMPs, named
tissue inhibitors of metalloproteinases (TIMPs), also exist. These enzymes and their
inhibitors are necessary for normal physiological processes such as cell migration,
wound healing, and tissue remodeling as well as being implicated in many pathogenic
processes such as cancer metastasis, multiple sclerosis, and aortic disease. Their role
in IA is believed to be a runaway process of ECM breakdown as collagen and elastin
are common substrates for several MMPs such as MMP-2, MMP-9, and MMP-12.46
MMP-9, also known as gelatinase B, is a proteolytic enzyme for collagen types 4, 5, 11,
and 14, as well as elastin, gelatin, and several other matrix proteins.47 This implicates
MMP-9 in the degradation of major components of vascular ECM and internal elastic
lamina, ultimately contributing to IA pathology.
Circulating plasma levels of MMPs including MMP-9 are increased following both
IA rupture as well as other forms of stroke. A dose response relationship has been
described between MMP-9 levels and poor outcome following stroke.48 Additionally,
other studies have demonstrated increased plasma levels of MMP-9 and decreased
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levels of its inhibitors in aSAH patients as compared with controls.49 The utility of
peripheral levels of MMP-9 are further demonstrated as they correlate with NIHSS
scores following stroke.49 MMP-9 levels have also been demonstrated to predict
ischemic stroke.50 However, as MMP levels, and MMP-9 in particular, are integral
components of tissue remodeling, it follows that these enzymes would be increased
following various events resulting in tissue loss and subsequent remodeling. This paper
is instead interested in if MMP-9 levels can be used prognostically prior to massive
tissue damage. A more complete review of MMP-9 in aneurysmal disease is included in
Chapter 2.

1.7 - Statement of the Problem
Intracranial aneurysms are a potentially deadly arterial malformation. However,
assessment of IA progression is challenging, expensive, and incompletely understood.
As such there is a need for better disease progression risk stratification in
conservatively managed patients. MMP-9 activity is implicated in IA pathogenesis and
progression, but it is unclear if this enzyme can be used prognostically as a biomarker
for disease progression.

1.8 - Goals and Objectives
To establish if elevated MMP-9 concentration in peripheral venous blood
samples of patients with conservatively managed IAs is associated with IA disease
progression over a follow-up period.
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1.9 - Hypothesis
There will be a statistically significantly greater proportion of subjects with IA
disease progression over the follow-up period among subjects with an unruptured
intracranial aneurysm (UIA) diagnosed within the last 3 years who are found to have a
plasma MMP-9 level greater than the 50th percentile among subjects within the study
group as compared to those with a plasma MMP-9 level less than the 50th percentile
when controlling for other risk factors.

1.10 – Relevant Definitions
1) Elevated MMP-9 level is defined as theMMP-9 level being greater than the 50th
percentile of MMP-9 levels among subjects.
2) Disease progression is IA growth or identification of aSAH during the study
period.
3) Growth is defined as any increase greater than 1 mm in aneurysmal length,
width, or height upon follow-up CTA or MRA.
4) Follow up period is defined as one year after plasma MMP-9 level measurement.
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CHAPTER 2 - REVIEW OF THE LITERATURE

2.1 - Search Criteria
We conducted searches of PubMed, Scopus, Ovid, and Cochrane Library
between January 2021 and April 2021. Searches were conducted using combinations of
MeSH keywords such as intracranial aneurysm, cerebral aneurysm, brain aneurysm,
berry aneurysm, saccular aneurysm, mmp-9, gelatinase b, 92-kda gelatinase, matrix
metalloproteinase, growth, increased size, volume, subarachnoid hemorrhage, SAH,
bleed, and intracranial hemorrhage. We also examined the references lists of all
studies. Preference was given to articles published within the last 10 years, however all
pertinent studies, reviews, and meta-analyses written in or translated to English were
included. Relevant non-human studies were included due to a relative lack of human
studies related to the exposure and outcome.

2.2 - Literature Review Introduction
This search demonstrated that MMP-9 presence in the IA wall is a cornerstone of
IA development and progression as well as significant in post rupture pathology.
Further, our literature review demonstrates the multifaceted and complex nature,
highlighting the many covariates at work in this complex disease. Whether plasma
levels of MMP-9 found in peripheral blood samples are associated with IA progression
as we have defined it is less clear, mainly due to a relative lack of studies on this
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subtopic. Widely quoted yet older and smaller studies suggest this is not the case while
newer studies, at times, suggest the opposite. No studies investigating plasma MMP-9
levels associated with IA growth were found.

2.3 - Review of MMP-9 in Aortic Aneurysm
Interest in this topic traditionally stems from studies suggesting that MMPs are
implicated in aortic aneurysm, which, while not the specific focus of our proposed study,
deserves brief mention here. A meta-analysis of studies reporting differential protein
expression in subjects with abdominal aortic aneurysm (AAA) spanning 106 studies
found that there was a significant increase in circulating MMP-9 levels as compared to
controls (SMD 0.67 ng/ml; p=0.002; I2 = 91%)1. MMP-9 activity within aortic tissue was
also increased significantly. Included in this analysis is the 2013 case control study
consisting of 120 subjects with AAA diagnosed between 1996 and 2007 and 78 controls
without aneurysmal disease. Plasma samples analyzed via enzyme linked
immunosorbent assay (ELISA) techniques revealed that MMP-9 levels were higher in
subjects with AAA vs controls (p<0.05).2 Interestingly, this difference remained
significant in the analysis of subjects with repaired AAA compared to those without
repair suggesting that increased MMP-9 levels remain elevated until repair (p<0.05), in
agreement with other studies3. Further, levels of MMP-9 mRNA demonstrated a 16.3fold increase in aortic aneurysmal tissues as compared to the aortic samples of
controls2. Another study found that elevated plasma levels of MMP-9 had a positive
predictive value of aortic aneurysm presence of 92.3% if levels were found to be >87.8
ng/mL (p<0.05)4
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2.4 - Review of MMP-9 in IA Animal Models
Much of the knowledge about MMP-9 in IA, however, stems from animal models
of the disease. Animal studies have demonstrated MMP-9 plays a significant role in IA
formation and growth, as well as the protective role of exogenous inhibitors of MMP-9 in
IA. The important role of MMP-9 in IA progression has been demonstrated in studies
using MMP analogs such as elastases and collagenases, as well as MMP inhibitors. 5, 6
In one study, IAs were induced in rats via hypertension and injection of elastase.5
Treatment with doxycycline, a nonselective MMP inhibitor, in doses of 40 mg/kg/day
reduced IA formation from 70% to 10% (p<0.05) and to 40% in MMP-9 knockout mice
(p<0.05). Conversely, other animal models demonstrate more severe IA formation via
MMP disinhibition in TIMP deficient mice relative to control animals.7
A 2007 paper demonstrates several core features of MMP-9 in the pathogenesis
of IA using a rat model.8 Investigators induced IAs via high salt diet, left carotid artery
and bilateral posterior renal artery ligations with resultant hypertensive flow through the
Circle of Willis according to a standard IA induction protocol. The anterior cerebral
artery/olfactory artery bifurcation of these animal subjects were then harvested at one
(n=11) or three months (n=10) post IA induction. MMP-9 tissue levels were then
assessed using real time polymerase chain reaction (RT-PCR) demonstrating increases
in MMP-9 at 3 months post induction vs age matched, non-IA induced control subjects
(p<0.01) expressed as a ratio vs beta actin, a non-MMP sensitive component of arterial
walls in agreement with many other studies on the topic.9, 10 Further, MMP activity was
assessed in a separate cohort (n=10) given therapeutic levels (50 mg/kg/day) of
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Tolylsam, a nonspecific competitive inhibitor of MMP-2, -9, and -12 vs a control group
(n=20) after IA induction. 90% of control rats developed both gross (advanced) IA
bulging and IEL discontinuity, with the remainder developing only discontinuity of the
IEL. In comparison, 50% of the experimental group developed advanced IAs and IEL
discontinuity, while the remaining 50% demonstrated only IEL discontinuity. While
neither the incidence of IA nor the degree of hypertension (control group:160.7±21.1
mm Hg; n=20; experimental group:161.2±12.2 mm Hg; n=10; p>0.05) were different
between the two groups, the rate of developing advanced IA changes was significantly
lower in the experimental group (p=0.013). The number of MMP producing cells within
the IA wall was also not significantly different between the groups (control
group:5.4±1.5; n=14; tolylsam group:5.1±1.3; n=10, p>0.05). In situ zymography for
gelatinase activity was demonstrated in the control rats and not found to be present in
the treatment group. Overall, this study demonstrates several core features of IA
disease such as the presence of MMP-9 in IA tissues, the protective role that inhibition
of MMPs can play, as well as the importance of other risk factors for IA development
such as hypertension.
The role of MMP-9 in the pathogenesis of IAs was further explored in animal
models demonstrating an increased level of MMP-9 mRNA by RT-PCR in rats with
induced IAs. 11, 12 In a 2020 paper, investigators attempted to examine the relative
concentrations of vascular degeneration substances via mRNA level analysis of 36 rats
with induced IAs relative to sham-operated rats. 11 Significant findings include higher
MMP-9 mRNA and a higher MMP-9/TIMP-2 mRNA ratio expressed in arbitrary units
(p<0.01), especially in the posterior cerebral circulation, in the experimental group vs
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the sham control group. This finding was supported by other studies where investigators
found that the total number of IAs formed and their rates of rupture were significantly
increased in rats that underwent IA induction with associated increases in the mRNA
levels of MMP-9 and MMP-9/TIMP2 ratios (p<0.01) vs sham-operated rats expressed
as mean and standard deviations in arbitrary units (alpha=0.05; power = 0.8; effect size
of 0.4). 12 These findings suggest that absolute levels of MMP-9 as well as the relative
level of activated MMP-9 play important roles in IA formation.
While the literature demonstrates that MMPs are strongly implicated in
aneurysmal pathogenesis and progression, there remains significant ambiguity
regarding the utility of MMP-9 measurements in blood samples of subjects with IA.
There are obvious mechanistic components to the relationship of MMP-9 and IA
disease as described above, however the relationship between MMP-9 and IA
progression over time requires further investigation.

2.5 - Blood Sampling of MMP-9 in IA Disease
This literature review found relatively few studies investigating the relationship
between MMP-9 concentration in the blood of human subjects with IAs and IA disease
progression despite the mechanistic relationship between them. Indeed, no papers were
found which assessed for increased size of UIA over a follow up period in relation to
MMP-9 levels. Instead MMP-9 concentrations were only related to IA presence or
rupture. Further, the papers that were found often present conflicting or contradictory
results.
Our search of the literature found several review articles stating that peripheral
blood levels of MMP-9 in relation to IA disease would be a fruitless course of
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investigation. 13, 14, 15 This appears to be largely due to the findings of a single, widely
quoted paper from 1997 by Kim et al. 9 Here the experimenters attempted to compare
MMP-9 levels in peripheral plasma samples in human subjects with known IAs (n=6) vs
those with no known IAs (n=6). The characteristics of each subject such as age, gender,
IA size, comorbid conditions, etc., are not presented. Results are presented qualitatively
as approximately the same visual appearance between control and experimental
samples for the activity of MMP-9 via gelatin zymography. The small sample size,
ambiguity of both control and IA group characteristics, as well as the qualitative nature
of result reporting should call into question the validity of this study. Nevertheless, this
study is widely quoted in the argument against the utility of peripheral blood sampling in
the assessment of IAs and likely contributed to reduction of interest in the topic of
assessing peripheral MMP-9 levels in IA disease.
The few studies directly measuring peripheral blood levels of MMP-9 following
Kim’s watershed paper demonstrate a large degree of variability in conclusions.
However, we have attempted to make it clear that these papers fail to distinguish if the
increase in MMP-9 found in subjects with RIA causes IA rupture or is caused by IA
rupture. One such study is a 2018 paper titled “Levels of MMP-9 in patients with
intracranial aneurysm: Relation with risk factors, size and clinical presentation” by Rojas
et al. 16 In this case-control study investigators attempt to evaluate the relationship
between plasma MMP-9 levels and the risk factors that are associated with ruptured
and unruptured IAs. To do this, peripheral blood samples were taken from 282 subjects
with IA and 286 age and sex matched control volunteers. Samples were assessed by
ELISA. In contrast to Kim’s 1997 paper, Rojas et al. thoroughly describe the
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characteristics of the study participants, including smoking, sex, age, hypertension,
family history of IAs, IA rupture status, and IA size. The results of the analysis
demonstrate increased MMP-9 levels, unfortunately expressed as unitless numbers, in
the patient group as a whole vs control (190.5 +/- 5.4 vs 149.7 +/- 4.7; p<0.0001), the
ruptured group vs control (p<0.0001) and the unruptured group vs control (p<0.0006).
Interestingly, no difference in MMP-9 levels were found between RIA and UIA
(p=0.4792), suggesting that MMP-9 levels do not change significantly post IA rupture, in
contrast to findings of other papers discussed below. Instead, results suggest MMP-9
levels can act as an indicator of IA presence regardless of rupture status. Further
analysis suggests that while MMP-9 levels of subjects with RIAs taken are significantly
higher than the control group, this difference is significant only in those subjects with
RIA measuring <12mm (p = 0.008) and >25mm (p = 0.047), with RIA measured
between 12 and 25 mm having a corresponding p-value of 0.062. This is even more
true of the UIA group as only the group with UIAs measuring <7mm being statistically
significant (p = 0.0071). All other UIA size groupings did not correlate with a significant
difference in MMP-9 levels when compared to controls. This may be due to suboptimized sampling methods as evidenced by the fact that only 23 subjects were
included in the 12-25mm RIA group, and the fact that the UIA group contained only 75
subjects, 32/75 (42.6%) of those subjects having an IA <7mm.
In contrast to these findings, several studies have found significant differences in
serum MMP-9 concentrations between ruptured and unruptured IAs groups. 17, 18 A 2007
paper titled “Matrix metalloproteinases and tissue inhibitors of metalloproteinases
expression in human cerebral ruptured and unruptured aneurysm” by Jin et al
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redemonstrated localized increases of MMP-2 and MMP-9 within IA walls and serum
samples in subjects with RIAs as compared with UIAs 19. To do this, IA tissue samples
were collected from 30 patients undergoing IA clipping. These 30 patients were split into
2 equal groups of 15 each by rupture status (15 RIA, 15 UIA). These samples were
subsequently analyzed for MMP/TIMP mRNA ratio levels using RT-PCR and compared
to MMP-2, MMP-9, and TIMP-1,-2,and -3 serum levels using ELISA. Results
demonstrate that MMP-9 mRNA levels were significantly associated with RIA vs UIA
(RIA: 5.21 +/- 0.87; UIA: 1.69 +/- 1.00, expressed as a numberless unit relative to the
enzyme GADPH, p = 0.05). MMP-2 mRNA levels were also significantly higher in the
RIA group. The serum level branch of this study demonstrated significant (p<0.02)
increases in MMP-9 and MMP-2 in RIA vs UIA as well (MMP-9: 1066 +/- 43 vs 120 +/27 ng/mL; MMP-2: 1047 +/- 33 vs 110 +/- 26 ng/mL respectively; p<0.02).
Immunohistostaining demonstrated increased levels of MMP-2, -9, TIMP-1, -2, -3 in the
RIA group relative to the UIA group as well. Despite these findings, the only conclusion
that can be reliably drawn is that MMP levels increase after rupture as it is unclear if
these elevations were the result or cause of rupture. Further loss of utility of the study is
realized as the study failed to take confounding variables or IA risk factors into account
in either data presentation or data analysis. As such, the prognostic utility of the study
cannot be assessed, nor can its conclusions easily inform our own hypothesis.
Despite these ambiguities and methodological shortcomings, similar conclusions
were found in a small case-control study evaluating the plasma levels of MMP-9
assessed via ELISA in human subjects with IA; 3 of which ruptured (mean diameter:
28mm) and 4 of which did not rupture (mean diameter: 13.5), vs a healthy control

21

20.

Venous plasma levels of MMP-9 were higher in IA subjects as compared to controls
(p<0.01) as well as higher in subjects with RIA and larger IAs (p<0.05), however exact
concentrations, means, and standard deviations are not stated. All IA subjects
underwent surgical clipping which allowed IA samples to be taken and assessed for
tissue expression of MMP-9. Here results were similar as above, with MMP-9 tissue
levels assessed via western blot analysis found to be significantly higher in RIAs vs
UIAs (P<0.01). This study’s use of a control group helps improve its internal validity in
contrast to Jin, et al. However, its external validity is marred by its small sample sizes
and poor data reporting.
A 2018 paper adds further confusion to the role of MMP-9 in IA disease.21 In this
paper the investigators carried out a population based case-control study where all adult
men and women of the city of Malmo, Sweden were invited to undergo baseline
examinations and peripheral blood draws to assess if various MMP levels would
correlate with spontaneous SAH over a follow up period from intake spanning 19911996 until SAH, death, emigration away from Sweden, or December 31, 2010,
whichever occurring first. Baseline examination included BP measurement, BMI, waist
circumference, smoking and alcohol habits, and current medications taken. Peripheral
blood samples were drawn and assessed for white blood cell count, MMP-1, -2, -3, -7, 9, -10, and -12. In total 79 cases with a median time from baseline to SAH of 8.5 years
(0.4-18.7 years) were compared to 261 controls matched for age and sex. MMP-9 levels
were found to be higher in cases of SAH as compared with controls, but they failed to
reach statistical significance in multivariate analysis (adjusted OR 1.06; 96%CI, 0.791.41; p=0.713). Only MMP-7 was significantly associated with an increase in SAH
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frequency when adjusting for confounders (OR 1.64; 95% CI, 1.19-2.27; p=0.0026). .
While this study suggests that peripheral sampling of blood to assess for MMP-9 is not
associated with SAH, it is unclear if the cases in this study included SAH stemming from
IAs as no imaging of cerebral vasculature was done during subject intake. Indeed, it is
not clear if vascular imaging was completed at all, or if it was, what proportion of cases
had undergone this assessment of IA presence as it is not readily clear how diagnosis
of SAH was identified in the cases. As such, it is not known if the cases had IAs during
the only assessment of MMP levels during intake or if these cases developed IAs after
MMP assessment, if at all. As such, this study does not present data directly impacting
or related to our own when scrutinized to a higher degree.

2.6 - Review of Confounder Variables
Several variables may affect either MMP-9 activity or IA progression. In general,
these confounders can be categorized as affecting IA rupture, IA growth, or MMP
functioning. The following review summarizes the studies most closely related to the
investigations of these topics.

2.6.1 - Confounding Variables Affecting IA rupture
Lesion and subject dependent variables related to increased risk of IA
progression has been a topic of study for many decades. It is generally established that
IA size, location, shape, and multiplicity play significant roles, as well as subject age,
sex, ancestry, smoking, SAH history, and hypertension status all contribute to IA
rupture. Indeed even IA growth itself may predict rupture.22 One large meta-analysis
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spanning 19 previously published studies and 6556 UIAs followed over 26,122 patient
years demonstrated that statistically significant risk factors for rupture were age >60
(RR 2.0; 95% CI, 1.1-3.7), female gender (RR 1.6; 95% CI, 1.1-2.4), Japanese or
Finnish descent (RR 3.4; 95% CI, 2.6-4.4), IA size >5 mm (RR 2.3; 95% CI, 1.0-5.2), IA
location in the posterior circulation aneurysm (RR 2.5; 95% CI, 1.6-4.1), and the
presence of a symptomatic aneurysm (RR 4.4; 95% CI, 2.8-6.8).23
These findings agree with other large-scale reviews such as the 2014 systematic
review of 6 prospective studies and 8382 participants with non-traumatic SAH as the
primary outcome and hazard ratios (HR) representing a 5-year IA rupture risk. This
study included hypertension as a risk factor, as well as stratified IA size with risk of
SAH. Specifically, hypertension history or presence (HR 1.4; 95%CI 1.1-1.8) IA size 79.9 mm (HR 2.4; 95%CI 1.6-3.6) IA size 10 mm-19.9 mm (HR 5.7; 95% CI 3.9-8.3) IA
size >20 mm (HR 21.3; 95% CI 13.5-33.8). If multiple IAs were present in a single
subject, the largest IA was used in analysis without individual IA analysis. Results are
comparable to the above reports for IA location in the anterior cerebral arteries (HR1.7;
95% CI 1.1-2.6), posterior comm artery (HR 2.1; 95% CI 1.4-3.0) posterior arteries (HR
1.9; 95% CI 1.2-2.9) relative to the Middle cerebral artery (MCA), and subject
geographic location of Japan (HR 2.8; 95% CI 1.8-4.2) or Finland (HR 3.6; 95% CI 2.06.2) relative to North America when controlling for other covariates using multivariate
Cox regression analysis.24 While the presence of any prior smoking history was not
reported in multivariate analysis, this definition appears to be a limited means of
determining the importance of smoking history, and is in contrast to other studies
suggesting that smoking increases relative risk of aSAH to as high as 7.3 when
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controlling for other variables.25 Instead, operationalization via pack-years likely
represent better methods of determining the importance of smoking on IA rupture.
Furthermore, familial history of aSAH and aneurysm growth over time were not
assessed, the latter of which is particularly important to our study. Additionally, 4 of the
6 studies used in this paper included studies with subjects who underwent clipping or
coiling of IAs during the follow-up period excluding them from inclusion in risk
calculations.26, 27, 28, 29 Selection bias found in exclusion of these subjects with a
potentially higher rupture risk may have skewed results by removing subjects with more
volatile lesions from data analysis. Furthermore, 6,486 of the 8,382 included subjects
were of Japanese descent (77.38% of all subjects), highlighting a source of selection
bias. Indeed, the above meta-analysis includes a widely quoted prospective cohort
study that followed 5720 adult Japanese subjects with a total of 6697 newly diagnosed
IAs measuring greater than 3mm.29 Relative to aneurysms that were sized 3 to 4 mm,
the hazard ratios (HR) for rupture were significantly increased for IA size categories 7 to
9 mm (HR 3.35; 95% CI, 1.87-6.00; p<0.01), 10 to 24 mm (HR 9.09; 95% CI, 5.2515.74; p<0.01), and 25 mm or larger (HR 76.26; 95% CI, 32.76-177.54; p<0.01). HRs
for IAs 5 to 6 mm were not statistically significant (HR 1.13 (95% CI, 0.58-2.22; p =
0.71). IAs in the posterior and anterior communicating arteries were more likely to
rupture as compared to IAs in the middle cerebral artery (HR 1.90; 95% CI, 1.12-3.21;
p= 0.02; HR 2.02; 95% CI, 1.13-3.58; p = 0.02, respectively). Irregularly shaped IAs
were also more likely to rupture (HR 1.63; 95% CI, 1.08-2.48; p = 0.02).
One retrospective cohort study of subjects with UIA demonstrated that risk
factors for rupture following the multivariate analysis were IA growth (OR 55.9; 95% CI
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4.47-700.08; p=0.002) and multilobulated IA shape (OR 17.4; 95% CI, 1.52-198.4;
p=0.022) demonstrated via serial CTA.22 These findings suggest that the limited
definition of IA progression of either rupture or growth is misleading as a risk factor for
IA rupture is IA growth. IA growth, therefore, requires its own dedicated discussion.

2.6.2 - Confounding Variables Affecting IA Growth
Several risk factors of IA growth have been proposed, many of which are the
same risk factors for IA rupture such as IA size, location, and shape as well as subject
characteristics such as hypertension, smoking, age, and sex. Of these only IA size,
shape, multiplicity, and location as well as subject smoking status and hypertension are
substantiated via meta-analysis. As such, in the absence of MMP exposure designation,
IA growth is mainly lesion rather than subject specific. For example, one systematic
review including 4972 UIAs included in 18 studies concluded that irregular IA shape,
posterior location, IA size greater than or equal to 5mm, and the presence of multiple
IAs in a single subject were associated with relative risks (RRs) of 2.32 (95% CI, 1.463.68; I2 =91%), 1.94 (95% CI, 1.32-2.38; I2=57%) 2.56 (95% CI, 1.93-3.39; I2 =98%) and
2.04 (95% CI, 1.56-2.66; I2 =90%) respectively.30 Other parameters such smoking at
baseline (RR=2.04; 95% CI, 1.56-2.66; I2=90%) and hypertension (RR=2.32; 95% CI,
1.46-3.68; I2=91%), were statistically significant, though high I2 values may discredit
these findings somewhat. This review included a retrospective cohort study which found
that the only risk factor for IA growth measured via serial MRI upon multivariate analysis
was original IA size >8mm (OR=7.25; 95% CI, 1.96-27.1; P=0.003 ).31 Other variables
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such as smoking, hypertension, IA multiplicity, and IA location were either not
statistically significant or not included in multivariate analysis.
Generally, these agree with the findings reported in a systematic review and
meta-analysis of IA growth, in which 23 studies and 7208 subjects were included.
Larger initial aneurysm sizes (OR 2.73; 95%CI, 2.21-3.36; p<0.00001) and smoking
history (OR 1.45; 95% CI, 1.07-1.98; p = 0.02) were associated with increased odds of
IA growth.32 Of the studies included in these systematic reviews, one multi-centered
prospective cohort of 557 non-Japanese subjects followed over a mean of 2.7 years
assessed risk factors for IA growth as measured via serial CTA or MRA. Multivariate
analysis via Cox logistic regression showed that size 7 mm-9.9 mm (HR 4.14; 95% CI
2.04-8.37), 10 mm-19.9 mm (HR8.06, 95% CI 3.89-16.72), >20 mm (HR12.92, 95% CI,
4.11-40.62) relative to size <7 mm predicted growth rather than rupture during a 5 year
follow up period.33 Interestingly this study did not find significant increases in hazard
ratios for IA growth associated with hypertension, age >70, history of previous SAH, or
IA location.

2.6.3 - Confounding Variables Affecting MMPs
While we have taken care to describe confounding variables that may affect the
primary outcome of our proposed study, time must be taken here to review possible
confounders of our study’s independent variable, summarized as either exogenous or
endogenous inhibitors of MMPs. Exogenous inhibitors of MMP-9 include Doxycycline,
Statins, and Aspirin, all of which are relevant to our study as they are commonly
prescribed medications for conditions with a high prevalence in the United States.
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Endogenous inhibitors of MMP-9, such as TIMPs discussed in previous sections, are to
be considered an intrinsic property of each subject's unique physiology and would
require their own serological assays and analysis to measure and understand. As such
they are outside the scope of this study. Therefore, we will restrict the discussion of
MMP inhibitors here to include only exogenous MMP inhibitors as they are well known
and feasibly accounted for in our study population.
Statins are cited in the literature as effectively lowering the levels or activity of
MMP-9 in animal models with associated protection against IA progression. Both
simvastatin and pitavastatin administration are correlated with significant reductions in
IA size, IEL thickness, MMP mRNA, and macrophage numbers within the IA wall in
several animal trials. 34, 35. However, a meta-analysis of 10 randomized, placebo
controlled human trials found no significant change in plasma MMP-9 levels with either
<12 weeks of statin therapy (SMD: -0.31; 95% CI, -0.81-0.19; p = 0.226) or >12 weeks
statin therapy (SMD: 0.15; 95% CI, -.91 to 0.60; p = 0.689).36 As such, there is no large
scale evidence to date that statin use will contribute significant confounding to our
proposed study. Despite this, we will nonetheless gather information about statin use in
our study population through intake and outcome assessment forms as these
medications are commonly prescribed and easily accounted for.
Antibiotics of the tetracycline class, specifically doxycycline, have also been
quoted in the literature as having a protective effect on aneurysmal progression through
an indirect MMP inhibitory mechanism. 37 One double-blind, placebo controlled trial of
44 subjects receiving 100mg of doxycycline twice daily for 6 months following AA repair
vs placebo, matched for multiple characteristics, found that plasma MMP-9 levels were
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significantly decreased below pretreatment baseline (-11.8% +/- 12.5%; p <0.06) as
compared to the placebo group (206% +/- 98.5%; p <0.04) with the difference between
the two groups also being statistically significant (p <0.009).38 This has been
substantiated in at least one additional AAA study.39 However, a larger randomized
placebo controlled trial of 286 subjects with AAA found that average AAA growth as
assessed by ultrasonography was greater in the group receiving 100mg of doxycycline
daily as compared to the placebo control group over an 18 month period (0.8mm; 95%
CI. 0.1-1.4 mm; p = 0.016)40 Other studies have found that a daily dose of 150mg of
doxycycline given over 18 months slows AAA growth compared to placebo (1.5mm
growth vs 3.0mm growth; p=0.01)41 Generally, however, these studies fail to adjust for
confounding variables, fail to account for compliance, and/or have small sample sizes,
all of which call into question the validity of reported findings.42 No studies were found
examining the effect of doxycycline in human IA disease, nor were any meta-analysis
found analyzing the body of information on doxycycline in AAA disease. Despite this,
while doxycycline in the general population is not likely taken over the extended time
period as found in the above studies, its use in the immediate time before or during our
study may represent an easily identified source of confounding that should be
accounted for in our statistical analysis.
Lastly, Aspirin has been suggested to be protective against IA progression
through an MMP-9 inhibitory mechanism.43 Meta-analysis of 5 studies consisting of
19,222 human subjects found that aspirin administration reduced the risk of nontraumatic or aSAH (OR 0.51; 95% CI, 0.34-0.76; p = 0.001), though the exact dose and
frequencies are not reported unambiguously.44 One case-control study used in this
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analysis compared aspirin use in 4701 subjects with 1,302 (27.7%) cases of aSAH vs
UIA found that daily dosages of 81 mg of aspirin decreased risk of rupture (OR 0.60;
95% CI, 0.45-0.80; p <0.05) with a further reduction in rupture risk with increased doses
to 325 mg daily (OR 0.65; 95% CI, 0.53 -0.81; p<0.01) when adjusting for confounders
such as age, sex, race, HTN, heart disease, and atrial fibrilation.45 A large case control
study using ISUIA data to assess the protective role of aspirin use in IA using 58
subjects with aSAH compared to 213 IA matched controls found that subjects who used
aspirin at least 3 times weekly had lower odds of IA rupture compared to those who
never take aspirin upon multivariate analysis using conditional logistic regression.46
Aspirin use is defined in terms of frequency per week, but no dosages are presented.
Another large meta-analysis of 10 studies consisting of 1,107,616 subjects reported an
increase in aSAH only in a subgroup that used aspirin for less than 3 months (OR
1.697; 95% CI, 1.175-2.452; p = 0.005).47 Despite this, the available data supports the
notion that aspirin administration offers a protective role against aSAH overall. As such
we will collect data on aspirin use immediately before and during our study as well as
include it in our data analysis given the potentially large potential for confounding.

2.7 - Review of Relevant Methodology
The following section reviews methodologies relevant to our proposed study. A
more detailed discussion of our study’s methods is found in Chapter 3.

2.7.1 - Study Design
Our proposed study is designed as a prospective cohort study to examine the
effects of MMP-9 levels in peripheral plasma samples on IA disease progression over a
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follow up period. The choice to design our study as a prospective cohort stemmed from
the lack of such studies with our exposure and outcome of interest in human subjects.
Preceding studies completed on the topic have been prospective cohort designs with
our outcome of interest but without assessment of our exposure of interest, 27, 29
retrospective cohort studies,24, 33, 48, 49, 50, 51 again without assessment of our exposure,
case-control studies using a limited definition of IA progression,16, 19 or small scale
randomized control trials performed using non-human subjects.5, 6, 7, 9,10, 52, 60, 62 This lack
of studies of the prospective cohort design using our outcome definition limits our ability
to assess the prognostic value of MMP-9 measurements via literature review alone.
This study will thus be the first prospective cohort study to our knowledge with our
outcome of interest related to MMP-9 levels. While we recognize that randomized
control studies are the gold-standard of study design, it would be impossible to
randomize our exposure of interest as this exposure is an intrinsic property unique to
each subject’s physiology. Additionally, randomized administration of exogenous MMP9 would be highly unethical as a breach of the beneficence principle. Further, a
retrospective study design would likely be underpowered as MMP levels are generally
not included in previous studies.

2.7.2. - Sampling of Study Population
The population we are interested in is composed of subjects with previously
identified IAs that have been conservatively managed. Identification of the sample
population will be made via searching the Yale New Haven Health system patient
databases for subjects recently diagnosed with an UIA as we are interested in IA
progression rather than IA development or genesis. Sampling of the population will then
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occur via consecutive sampling, with each subject contacted and recruited from most
recently imaged IA to most distantly imaged IA until our requisite sample size is met.
This is in contrast with other studies on the subject, largely because these previous
studies did not include reimaging of IAs as part of their outcome assessment or due to
their retrospective study design. Despite this lack of precedence, we feel as though this
method of population sampling is the most cost-effective manner to assess for IA
progression as it limits the number of resources required to obtain baseline imaging as
well as the amount of time variation between baseline imaging and outcome imaging.
Previous prospective cohorts on the topic enrolled subjects as they were diagnosed with
IA, largely via incidentally identifying IAs. This approach to enrollment is highly time
consuming, with one study taking 4 years to recruit 448 subjects.27 One Japanese study
prospectively recruited a large number of subjects over a shorter period, however this
was likely only possible due to aggressive IA screening protocols common in Japan 29
As such we feel as though this sampling method minimizes time and economic costs
required for sampling to take place, as well as sampling bias while still maximizing the
validity or fidelity of the data being gathered, while working within the framework of
established domestic guidelines. Despite this, sampling bias may still be introduced by
this method as it favors a sample with smaller, and thus perhaps more stable IAs as
intervention decisions, while ultimately up to the patient, is advocated for larger IAs. As
such, our study will attempt to draw conclusions about IAs from a sample that may be
intrinsically more stable as less stable lesions will be treated and consequently excluded
from our study.
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2.7.3 - Inclusion and Exclusion Criteria
The inclusion and exclusion criteria of our proposed study have been designed to
be consistent with those of the majority of previous studies and reviews mentioned in
chapter 1.53, 54 Generally these aim to exclude subjects who likely do not have MMP
driven pathogenesis of their IAs such as those with connective tissue disorders,
subjects with inherited disorders or malformations known to increase risk of IA, as well
as those that cannot complete the process needed for outcome measurements, or
those with surgically treated IAs. A further discussion of our study’s inclusion and
exclusion criteria can be found in Chapter 3.

2.7.4 - Exposure Determination
Our primary exposure will be plasma levels of MMP-9 collected from the
peripheral venous vasculature and assessed by the ELISA method. This method of
measurement was chosen because of its use in prior studies, ease of acquisition, and
minimal associated risks as our study is interested primarily in developing a feasible
prognostic biomarker for IA progression validated by traditional imaging methods. 13, 16,
38, 55, 56

Despite this, our literature review demonstrated that many studies preferred to

assess the presence of a variety of MMPs in vascular walls themselves by other
techniques such as tissue zymography largely due to subject populations undergoing
surgical treatment of IAs or from non-human subject harvests.57, 58, 59, 60, 61, 62, 63, 64
However, as discussed above, these studies necessitate surgical intervention in order
to acquire tissue samples and thus cannot be included in our conservatively managed
study population. Further, our literature review did not find studies which attempted to
define normal or healthy concentrations of MMP-9. Indeed, sparingly few studies were
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found which assessed MMP-9 concentrations in healthy controls.9, 16, 20, 21 Even with
such control values, it is impossible to determine if these are normal or healthy
concentrations, or how an unhealthy concentration should be defined given this lack of
large-scale data. As such, our exposure determination will be defined from within our
study population relative to itself as greater than or less than the 50th percentile
concentration of MMP-9 within the sample population.

2.7.5 - Outcome Definitions
The outcome of interest in this study is IA progression defined as either a 1mm or
greater increase in IA size in any dimension as assessed by CTA or MRA, or
development of SAH. As in previous decisions regarding study design, our definition of
growth was chosen as it agrees with the majority of other studies on the topic and is the
most easily verified.29, 31, 33, 65, 66, 67, 68 Despite this, a number of other growth definitions
have been used including a 2mm or greater increase in any dimension or a 1.5X
increase in diameter.22, 48, 67, 69, 70 Occasionally investigators will include “obvious
change in shape” or the development of a bleb in the aneurysmal wall, however
qualitative assessments of IA progression are to be avoided in our study as they are
less easily verified and can require majority consensus of a panel of radiologist for
outcome designation.51 We also chose to include the development of SAH in our
outcome assessment as this is seen as the most important and obvious outcome
related to our study.
An additional aspect of our study design is the inclusion of a single
neuroradiologist used to make outcome measurements. While this may be seen as
introducing the risk of information bias perhaps avoided by using a panel of radiologists
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for outcome designations as previously mentioned, studies on the topic do not support
the notion of high intra-observer variability when making these types of assessments
Indeed, one study comparing intra and inter-observer differences in IA measurements
noting an intraclass correlation coefficient (ICC) of 0.97 when measuring IA height and
0.98 when measuring IA width using CTA (95% CI), when a value of 1 indicates perfect
agreement.70 Similar results were found when using MRA in the same study.
Interobserver ICC by comparison are only slightly worse at 0.96 and 0.98 via CTA for IA
height and width respectively and 0.95 and 0.94 via MRA for height and width
respectively. Our study thus chose to avoid unnecessary complications in outcome
assessment made by multiple observers in favor of a single observer as the quality of
data obtained by either method is equivocal.
Further, we chose to assess IA progression via either CTA or MRA as long as
the outcome assessment is the same as the most recent imaging technique for the
subject in question. Again, while this may appear to introduce information bias due to
the difference in imaging modality between subjects, a review of the available literature
does not support this notion. When comparing IA measurements made by 4
independent radiologists using CTA and MRA against measurements made by invasive
angiography, a combined average variance of +16.1% (p=0.03) for CTA and -15.9%
(p=0.03) for MRA was found.72 Similar results have been reported by other
investigators.73 Thus, while significant bias may be found in interchanging imaging
modalities for any one subject and different modalities over or underestimate IA size,
this bias will be significantly avoided by making outcome assessments in the same
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modality as baseline measurements and our study is interested in change of IA size
over time rather than total IA size.

2.7.6 - Sample Size and Statistical Significance
Although the theoretical link exists between MMP-9 and IA progression, in
addition to the number of studies mentioned above that support this relationship, we
cannot deny the heterogeneity of conclusions on the topic that, while not suggesting a
protective role of MMP-9 on IAs, may still exist. As such we have chosen to utilize a
two-tailed calculation to be able to detect this relationship in either direction. We will
follow an analysis based on an alpha of 0.05 and a beta of 0.20 as this most closely
follows the statistical methods as outlined in the above literature review. Further, while
IAs are relatively common in the population at large, most of these lesions are
undiagnosed, forcing us to identify subjects retrospectively via patient databases to
meet our need for a sample size of 282 subjects. Our complete sample size calculation
can be found in Appendix C.

2.8 - Conclusion
This review demonstrated that our exposure of interest has been an ongoing
topic of exploration for greater than 20 years. While initial, low-quality studies suggested
that MMP-9 concentration in blood samples would be a conceptual dead end, renewed
interest in the topic seems promising as multiple animal studies have demonstrated
interesting pathological findings related to the exposure as well as a small number of
human studies with similarly intriguing results.
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This review also demonstrated the relative lack of prospective cohort studies with
our outcome of interest as we defined it, despite several large-scale prospective cohort
studies relating risk factors for IA rupture over time. Despite this, several studies have
attempted to expand this limited definition of IA progression to include IA growth, though
these have largely been of a retrospective design. As such, ours is the first study of its
kind to assess for a more complete definition of IA progression as it relates to MMP-9
exposure via a prospective study design. These retrospective studies, nonetheless,
have highlighted many important risk factors and confounders for IA rupture and growth
which will need to be accounted for in our proposed analysis below.
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CHAPTER 3 - STUDY METHODS

3.1 - Study Design
This prospective study will retrospectively identify subjects who have had at least
one intracranial aneurysm identified for the first time via CTA or MRA within the last 3
years to determine the association between plasma MMP-9 concentration in peripheral
venous blood of subjects with UIA and IA disease progression over a one-year follow-up
period. A consent form to participate in the study will be presented to each subject after
identification from the Yale New Haven Health (YNHH) system patient database. The
consent form will be reviewed with the patient and signed to enroll the subject in the
study. Demographic and pertinent medical data will be extracted via chart review and an
intake survey. A copy of our intake survey can be found as part of our information form
in Appendix A. These subjects will next have plasma MMP-9 concentration measured
once at the time of or soon after enrollment and then be prospectively followed for one
year starting on the date of their blood draw at which time they will have a repeat
imaging assessment of their intracranial vasculature to assess for aneurysmal growth.
Choice of imaging modality upon follow up will be the same modality as was used in the
subject’s most recent imaging study in order to avoid mismeasurements related to
alternating modalities. As repeat imaging every 1-2 years is recommended by national
guidelines, all subjects included in the study are expected to have recent imaging with
which to compare our outcome imaging with. While this may introduce variation in the
timeline between baseline and outcome imaging measurements, this variation will be
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minimized as compared to previous studies as discussed above while still maximizing
our study’s feasibility and internal validity. There are no interventions related to this
study.

3.2 - Study Population and Sampling
This study's population of interest is limited to subjects found within the YNHH
system with an intracranial aneurysm diagnosed within the last 3 years who have
chosen an observational treatment course. Criteria for exclusion will include prior
aneurysmal surgical treatment, prior history of subarachnoid hemorrhage, history of
blood clotting disorders such as Von Willebrand's Disease, Hemophilia, Factor 5 Leiden,
or concurrent anticoagulation therapy, an inability to tolerate IV contrast as defined as
previous contrast induced nephropathy, a history of intravenous contrast induced
anaphylaxis, or a history of renal insufficiency, conditions associated with unstable IAs
such as Polycystic Kidney Disease, Marfan’s syndrome, type IV Ehlers-Danlos
syndrome, neurofibromatosis type 1, alpha-1-antitrypsin deficiency, fibromuscular
dysplasia, pheochromocytoma, Klinefelter's syndrome, and congenital malformations
such as coarctation of the aorta, bicuspid aortic valve, and intracranial arteriovenous
malformations as these patients generally follow a distinctly different treatment course,
present at earlier ages, or have a different underlying pathology of their IAs. 1 We will
also be forced to exclude subjects who have had baseline imaging only via traditional
angiography as we are not willing to repeat this method of outcome assessment
because it carries additional risks associated with its invasive nature. We will not
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exclude patients based on IA size or other indications for IA surgical treatment if the
subject consents to accepting the risk of choosing conservative treatment.
Sampling will take place via peripheral venous blood once at a Yale University
affiliated site. Quantification of plasma MMP-9 levels will be made via Enzyme-linked
immunosorbent assay (ELISA).2 Follow up imaging will take place one year after this
blood sample is collected and compared to the most recent aneurysm image taken prior
to the start of the study period. All aneurysm measurements will be made by a single
neuroradiologist blinded to subject identifiers and exposure status. The use of a single
neuroradiologist may introduce an element of bias unique to this single observer,
however this intra-observer variation has been found to be minimal by previous studies
discussed above. Further, the use of a single observer will avoid inter-observer
differences in measurements and evaluation.
The population under study is composed of subjects with IAs demonstrated via
MRA or CTA who have elected for a nonoperative treatment course. Blood sampling will
occur soon after enrollment. Repeat imaging will occur one year after blood collection.
Subjects will be split into exposure or non-exposure (control) groups based on the
presence or lack of increased MMP levels as defined by being above or below the 50th
percentile of MMP blood concentration within the study group.

TABLE 1: Eligibility Criteria
Inclusion Criteria

Exclusion Criteria

IA diagnosed < 3 years prior

Aneurysmal hereditary syndromes

Elected for conservative treatment

Prior IA surgical treatment

Age greater than 18

Bleeding disorders
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Most recent IA imaging by CTA or MRA

Current anticoagulation therapy
Cardiovascular congenital malformations
Prior aSAH
Inability to tolerate IV contrast

3.3 - Recruitment
Recruitment will be made via phone and email contact with eligible subjects
found by using YNHH patient databases. We plan to recruit subjects with at least one IA
identified within the last 3 years who have elected for conservative management.
Retrospectively identifying subjects will minimize recruitment time. Each site will be
assigned a research assistant who will provide information about the study to subjects
and clinicians, enroll eligible patients, perform intake assessments, and obtain informed
consent.

3.4 - Subject Protection and Confidentiality
We will obtain Yale University’s Institutional Review Board approval prior to
recruitment of subjects. Study personnel will access all participant electronic medical
records (EMRs) on university-approved, encrypted, and secure electronic devices after
completion of Health Insurance Portability and Accountability Act (HIPAA) training and
Yale Human Subjects Protection training. Protected health information (PHI) not in
electronic form will be stored within a locked cabinet in the locked office of the principal
investigator to which only direct research staff will have access. All PHI will be disposed
of in a secure manner after the study is completed.
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Participants will be required to grant written, informed consent in order to
participate in the study. An example of the informed consent form can be found in the
Appendix B. Study personnel will explain the consent form in a simple manner to allow
participants to have the opportunity to ask questions and discuss concerns prior to
consenting. The consent form contains a study description, duration of participation, and
potential risks and benefits of the study in a style that is intelligible to a 6th grade
reading level. It will be available in English with translation to other languages if needed.
Interpreter services will be utilized as needed for other languages. For those who are
unable to read, informed consent will be obtained after an oral presentation with a thirdparty present to ensure all information is accurately represented.

3.5 - Study Variables and Measures
3.5.1 - Independent Variable
The independent variable or exposure of this study will be MMP-9 levels
measuring greater than the 50th percentile among study participants with an equal
number of participants in each group. This measurement will be taken once starting at
the onset of the study period. MMP-9 exposure status is measured once as they are
assumed to be present on a chronic basis. Samples will be collected from the peripheral
venous system at or below the level of the subject's antecubital fossa into a 4.5mL tube
with ethylenediaminetetraacetic acid (EDTA) each month. The plasma will be separated
from the total blood and stored frozen at -80 degrees C until analysis. Samples will then
be sent to a participating laboratory where plasma MMP-9 levels will be measured using
ELISA-DuoSet ELISA, DY911, R & D Systems.
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3.5.2 - Primary Dependent Variable:
The primary dependent variable is IA disease progression as defined as IA
growth greater than 1mm in any dimension or development of aSAH during the followup period. This definition agrees with previous studies discussed above in an attempt to
establish outcome homogeneity. We will not include the formation of a bleb or change in
IA shape in our outcome definition as this represents a subjective determination that will
likely result in an increase in IA size and is thus better evaluated by this objective
measurement. Determination of this growth will be made by a single, blinded
neuroradiologist. Determination of IA rupture will be made by the attending radiologist at
the presenting institution if a diagnosis of aSAH is made.

3.5.3 - Confounding Variables
Known confounders or secondary variables that contribute to aneurysmal growth
as identified in the above literature review such as age, baseline aneurysmal size,
female sex, hypertension status, smoking history, medications, family history, previous
aSAH will be collected at intake through a combination of intake survey, radiological
assessment of baseline images, and chart review. A summary of these variables and
how we plan to test them can be found in Table 2.

3.6 - Methodology Considerations
3.6.1 - Blinding of Exposure
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Subjects will not be informed of their exposure status until after the study is
completed, as it is unclear if exposure carries any risk. Exposure status will also not be
released to any clinical teams as this may unnecessarily influence treatment decisions.
Exposure status will be blinded from the neuroradiologist assessing our outcome by
assigning subjects a randomly generated numerical code and removing any potential
identifiers or exposure status information.

3.6.2 - Blinding of Outcome
Information related to disease progression assessed as our outcome upon study
completion will be considered medically necessary information and will likely influence
treatment decisions. As such, subjects will be offered the option to obtain the results of
their imaging at the time of their outcome assessment in which to share with their
treatment teams in order to facilitate proper treatment decisions. In this way, there will
be no blinding of outcomes related to this study. This is not seen as a threat to the
validity of the study as the study is considered complete upon outcome image
acquisition.

3.6.3 - Assignment of Intervention
Subjects will be assigned to exposure or non-exposure groups based on average
MMP-9 level. The unexposed group is defined as those subjects whose MMP-9 level is
below the 50th percentile of the total cohort. While this method of exposure assignment
may be seen as introducing a form of sampling and information bias as it is unknown
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how MMP-9 levels will be distributed within the sample, no normal or healthy level of
MMP-9 concentration can be found in the literature to which compare to.

3.6.4 - Adherence
It is believed that recruited subjects will be highly motivated to remain in the
study due to the severe nature of their condition and the established need for periodic
monitoring. However, it is critical to the study that subjects attend their appointments for
blood sampling and reimaging. As such, patients will be reminded of their appointment
one week in advance to the date of their appointments. However, if the initial
appointment is missed, the subject will be contacted via phone and scheduled for blood
draw at their earliest convenience but not to exceed one month after their missed
appointment in order to minimize deviations from our proposed study timeline. If the
follow up appointment is missed the subject will be contacted by phone and email to
schedule outcome imaging up to one week after their missed appointment in order to
minimize variations in outcome assessment timelines. If a subject is unable to
reschedule appointments in this time frame they will be dropped from the study. We
recognize this may introduce a degree of compliance bias. However, we expect
adherence to be extremely high as a result of our study design, namely that we have
defined our outcome of interest to include those subjects who experience an IA rupture
who would otherwise not be able to be assessed for IA growth.

3.6.5 - Monitoring of Adverse Events
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It is possible that subjects experience aSAH or symptoms warranting
reevaluation of their IA during the study period. If this should occur the subject should
call 911 to get evaluated as soon as possible and follow all recommendations of his or
her care team. This will likely include urgent neurovascular imaging via CT scan to
assess for aSAH. If repeat imaging shows aSAH or marked increase in IA size
warranting surgical intervention, then the subject will be included in the study as the
outcome of interest has been demonstrated, with no other intervention required from the
study administrators. These patients should undergo whichever procedure is
recommended by their care team. If imaging occurs during the follow-up period that
does not demonstrate IA progression, but the subject undergoes IA surgical or
endovascular treatment, then the subject will be dropped from the study in agreement
with previous study protocols as above. If repeat imaging occurs during the follow up
period that does not show IA progression and the subject does not undergo IA
intervention, the subject will still be included in the study if they can undergo repeat
imaging at the end of the follow up period.

3.6.6 - Data Collection
Subjects will fill out an intake survey to assess patient demographics such as
age, sex, height, weight, smoking history, hypertension status, family history, allergies,
medications, and presence of IA symptoms, among other parameters. A complete
example of the intake survey can be found in Appendix A. The electronic medical record
will be referenced to gather aneurysmal specific characteristics such as size, location,
most recent imaging, most recent imaging modality. MMP-9 levels will be collected once
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starting as soon as possible after consenting. Outcome data via imaging will be
collected one year after the last exposure measurement is collected by a single
neuroradiologist blinded to subject identifiers and exposure status. While a single
observer introduces a potential for intra-observer information bias, multiple observers
have the risk of introducing their own inter-observer information bias. Further, data
suggests that this intra-observer bias is generally minimized as described in Chapter 2.

3.6.7 - Sample Size Calculation
The proposed sample size is 282 subjects calculated using Power and Precision
4 Software and the UCSF Sample Size Calculator.3, 4 Several assumptions were
required to arrive at this sample size. It was assumed that all subjects with intracranial
aneurysms could be placed into two groups, either the elevated MMP-9 group (MMP+),
or the non-elevated MMP-9 group (MMP-). Further it was assumed that growth rates will
be increased in the MMP+ group as compared to the MMP- group, although this
parameter was not specifically measured in previous studies assessing growth risk.
Thus, any study describing the proportion of subjects with growing IAs by a variety of
variables contains a mixture of MMP+ and MMP- subjects, where MMP+ subjects
contribute to the proportion of growing IAs at a higher rate, and MMP- subjects, while
still contributing to the proportion of growing IAs depending on their co-variables for
growth, grow slower or less frequently and thus decrease the proportion of growing IAs
as a whole.5 ,6 The conclusion of these studies thus acts as an average proportion of
growing IAs in subjects with elevated and non-elevated MMP levels. Our estimated
effect size is then found by assuming that the proportion of growing IAs in the
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unmeasured MMP+ subjects of previous studies will be 5% higher than the total number
of growing IAs growing due to other risk factors for growth, while the MMP- group will be
5% lower than the total but still grow according to their own non-MMP risk factors for
growth, for an effect size of 10%. The proportion of aneurysms growing in one year was
assumed to be 9% based on work by Villablanca demonstrating that 18% of aneurysms
grew over a period of 2.2 years.6 Thus, we assume that 4% of MMP- subjects will
progress and 14% of MMP+ subjects will progress over one year. Setting the power of
our proposed statistical analysis at 80% for a two-sided hypothesis, with a confidence
interval of 95%, with the above described effect size of 10% allows us to arrive at the
sample size of 256 subjects. The additional 26 subjects proposed are to account for an
estimated 10% loss to follow up over the one-year study period. Since mortality is an
expected complication associated with our outcome of interest of disease progression,
subject mortality will not affect our study population size and thus need not be factored
into our sample size calculation.

3.6.8 - Statistical Analysis
The characteristics of our sample population will be analyzed by univariate
analysis to assess for common factors influencing IA progression as summarized in
Table 2. Bivariate analysis will be conducted using the Chi-squared test of significance
to assess for aneurysm progression, defined dichotomously as either present or not
present, in the setting of MMP-9 levels with a two tailed test for significance set as
p<0.05. Final models will be adjusted for known confounders, identified as categorical
variables, reaching a significance level of p<0.05 using multiple logistic regression to
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assess if these confounders share an association with our exposure of interest as
established by preceding studies mentioned above. While a potential for selection and
information bias exists in defining exposure status according to percentiles defined
within the study group, normal or healthy levels of MMP-9 have not been established in
the population at large, making it difficult to define high or low levels in other ways.
Sensitivity analysis will be completed on our sample’s MMP-9 level distribution to
identify an alternative exposure cutoff associated with IA progression.

Table 2: Subject and IA Characteristics with Statistical Tests
Subject
Characteristics

MMP - Group

MMP+ Group

p-value

Age

mean ± SD

mean ± SD

ANOVA

Sex at Birth

n (%)

n (%)

Chi-square

Pack Years

mean ± SD

mean ± SD

ANOVA

Hypertension

n (%)

n (%)

Chi-square

Japanese Ancestry

n (%)

n (%)

Chi-square

Finish Ancestry

n (%)

n (%)

Chi-square

Doxycycline Use

n (%)

n (%)

Chi-square

Aspirin Use

n (%)

n (%)

Chi-square

Statin Use

n (%)

n (%)

Chi-square

IA Size (most
recent)

mean ± SD

mean ± SD

ANOVA

MCA IA Location

n (%)

n (%)

Chi-square

Posterior IA
Location

n (%)

n (%)

Chi-square

IA Characteristics
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Anterior IA Location n (%)

n (%)

Chi-square

IA Multiplicity

n (%)

n (%)

Chi-square

Previous IA Growth

n (%)

n (%)

Chi-square

3.7 - Timeline and Resources
Pending Institutional Review Board (IRB) approval, we will retrospectively identify
and recruit subjects with an UIA first diagnosed within the last 3 years over a period of 6
months. During recruitment, peripheral blood sampling of subjects to determine
exposure status will begin. Repeat imaging will occur one year after blood sample
collection, allowing the study to be completed within 18 months. After this we will
interpret the results and report our findings.
Study personnel will include one principal investigator, Dr. Kevin Sheth, one coprincipal investigator, Peter Stampfel, to coordinate blood sample collection and
analysis, intake survey administration, electronic medical record data collection, and
statistical analysis upon study conclusion, and one neuroradiologist to obtain outcome
measurements.
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Chapter 4 - Conclusion
4.1 - Advantages
Our study has several strengths including the use of a prospective design,
expanded definition of IA progression, an exceptional ethical profile, and an efficient
subject recruitment
We propose a prospective cohort with repeat imaging obtained over shorter
periods relative to previous studies. This will allow us to compare our exposure to a gold
standard of disease monitoring in a way uncommonly employed in previous studies. Our
study’s prospective design also allows us to include a more comprehensive definition of
IA progression. As other studies have avoided acquiring repeat imaging and thus were
only able to define IA progression as IA rupture, they failed to acquire data on IA growth
and thus the risk of IA rupture in UIAs. Our prospective design with repeat imaging on
outcome assessments allows us to include RIAs and growing but currently UIAs within
our definition of disease progression.
Additionally, our study design is exceptionally ethical as it fits within the
recommended IA monitoring guidelines established by the AHA. As such it does not
require significant deviation from standard of care. Further, the only deviation from
standard of care is a peripheral venous blood draw and does not represent any
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meaningful risk to the subjects. The only subjects included are those who have chosen
conservative treatment. This minimal deviation from standard of care also suggests that
our study design has maximized its feasibility while still acquiring high quality data. IA
imaging is time consuming and expensive, leading many previous studies to avoid a
prospective design, instead opting for retrospectively collected data. However, this has
necessarily led to lower quality data as follow up imaging has been acquired on a highly
variable timeline.
Retrospectively identifying subjects with IAs to be included in our prospective
cohort also reduces the amount of time that would be needed to recruit subjects as they
are identified upon presentation as is done in traditional prospective cohort studies.
Further, using recently acquired images that are independently evaluated by our blinded
neuroradiologist reduces the time and cost of acquiring our own intake/baseline
imaging.

4.2 - Disadvantages
Despite these advantages as well as our significant efforts to optimize our study
design, we acknowledge that this study has several shortcomings. Perhaps the main
shortcoming of this study is that it measures a single MMP. While we have attempted to
choose the MMP with the strongest evidence for its contribution to IA disease, it is likely
that it is only one of many enzymes contributing to the formation and progression of IA
lesions. Thus, future studies may find it fruitful to expand their IA markers to include the
enzymes, second messengers, and inflammatory cells likely to be found implicated in IA
progression upon a broader search of the scientific literature. Additionally, several
studies have demonstrated the importance of endogenous inhibitors of MMPs. Further
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studies on the topic may find it worthwhile to include TIMP levels and MMP/TIMP ratios
into their exposure determination.
While it is well established that MMPs as a family of enzymes play an important
role in the formation and progression of aneurysms, some authors have suggested that
aneurysm growth is episodic.1, 2 This study will then only succeed in taking a snapshot
in time via its short assessment period for MMP-9 exposure. This will likely lead to
under or overestimating exposure levels and outcomes. As such, the short period of
exposure evaluation proposed in this study likely represents a narrow time window
which increases the chance that any one subject will be misplaced in the wrong
exposure group. Ideally, MMP-9 levels will be drawn as regularly as possible to avoid
this misclassification of exposure, however it is unlikely that subjects will be willing to
adhere to such numerous blood collections. Our study attempted to maximize its
feasibility at the expense of absolute validity.
Lastly, there was a lack of reliable information related to the calculation of our
effect size. This required us to make several assumptions that, while not wholly
unjustifiable, are possibly inaccurate. As such, our study is at risk of being overpowered
or underpowered.

4.3 - Health Significance
Intracranial aneurysms are incredibly common, extremely dangerous, and difficult
to monitor via traditional means of MRA or CTA. Further, our collective understanding of
the pathological processes at work is still in development. These factors, when
combined, leave many patients with this condition at significant risk for deadly or
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debilitating consequences. The development of an easily acquired alternative to disease
progression as proposed in this study would be invaluable to many individuals harboring
IAs as they may decrease more invasive and expensive disease progression
assessments.
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Appendices
Appendix A: Subject Information Form

Section I: To be completed by Subject
Name:_______________ Sex at Birth:_________ DOB:_____________ Age:______
(dd/mm/yy)
Phone Number:________ Email:__________
May we leave a voice message for you? Yes____ No____
Address:_____________________________________
City:__________________

State:____________ Postage Code:_______________

Have you ever been diagnosed with high blood pressure? Yes____ No____
Have you ever been diagnosed with kidney dysfunction? Yes____ No____
Do you use tobacco? Yes____ No____ If yes, how much per day? ________
Are you of Japanese ancestry? Yes____ No____
Are you of Finish ancestry? Yes____ No____
Have you ever had a reaction to intravenous or IV contrast? Yes____ No____
Do you or any members of your family have any of the following conditions:
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Polycystic Kidney Disease: Yes____ No____ Marfan Syndrome: Yes____ No____
Ehlers-Danlos Syndrome: Yes____ No____ Klinefelter's syndrome: Yes____ No____
Neurofibromatosis type 1: Yes____ No____
Alpha-1-antitrypsin deficiency: Yes____ No____
Fibromuscular dysplasia: Yes____ No____ Pheochromocytoma: Yes____ No____
Have you ever been diagnosed with coarctation of the aorta OR bicuspid aortic valve
OR intracranial arteriovenous malformations? Yes____ No____
Have you ever been diagnosed with a bleeding disorder?: Yes____ No____
Have you ever been diagnosed with a blood clotting disorder?: Yes____ No____
If yes, what is the bleeding OR blood clotting disorder named?: ___________________
Have you ever had brain OR aneurysm surgery? Yes____ No____
If yes, when?:________

Section II: To be Completed ONLY by Research Staff upon Intake
Subject MRN:________________

Subject Identification Code:_________________

Date of Blood Draw:________________ MMP-9 Level (ng/ml):__________________
(dd/mm/yy)
Heart Rate:_______ Blood Pressure:____/____ Respirations:______ O2 Sat:________
Height (cm):_____________ Weight (Kg):______________
Medication

Dose

Frequency
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Allergic To

Effect

Date of most recent cerebral vascular imaging:_____________
Imaging type: CTA:___ MRA:___ Number of IAs:_______
IA symptoms present?:Yes__ No__
IA Identification Number:_______ IA H x L x W(mm):___x___x___ IA location:________
IA Identification Number:_______ IA H x L x W(mm):___x___x___ IA location:________
IA Identification Number:_______ IA H x L x W(mm):___x___x___ IA location:________
IA Identification Number:_______ IA H x L x W(mm):___x___x___ IA location:________
IA Identification Number:_______ IA H x L x W(mm):___x___x___ IA location:________
IA Identification Number:_______ IA H x L x W(mm):___x___x___ IA location:________
IA Identification Number:_______ IA H x L x W(mm):___x___x___ IA location:________

Section III: To be Completed ONLY by Research Staff upon Study Completion
Heart Rate:________ Blood Pressure:____/____ Respirations:______ O2 Sat:_______
Height (cm):__________

Weight (Kg):___________ IA symptoms?:Yes____ No____

Incidence of SAH during study period? Yes____ No____
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Incidence of subject death during study period? Yes____ No____
If yes, when________ Cause of death:________
Imaging type: CTA:___ MRA:___

Date of Imaging:_____________
(dd/mm/yy)
IA Identification Number:_______ IA H x L x W(mm):___x___x___ IA location:________
IA Identification Number:_______ IA H x L x W(mm):___x___x___ IA location:________
IA Identification Number:_______ IA H x L x W(mm):___x___x___ IA location:________
IA Identification Number:_______ IA H x L x W(mm):___x___x___ IA location:________
IA Identification Number:_______ IA H x L x W(mm):___x___x___ IA location:________
IA Identification Number:_______ IA H x L x W(mm):___x___x___ IA location:________
IA Identification Number:_______ IA H x L x W(mm):___x___x___ IA location:________
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Appendix B: Informed Consent Form

Informed Consent form for adults participating in the study titled “The Effect of
Plasma Levels of Matrix Metalloproteinase-9 on Intracranial Aneurysm
Progression”
Title of Study: The Effect of Plasma Levels of Matrix Metalloproteinase-9 on
Intracranial Aneurysm Progression
Principal Investigator: Kevin Sheth, MD
Co-Principal Investigator: Peter Stampfel
Affiliation: Yale University School of Medicine and Yale New Haven Health System
This Informed Consent Form has two parts:
● Information Sheet (to share information about the research with you)
● Certificate of Consent (for signatures if you agree to take part)
You will be given a copy of the full Informed Consent Form

PART I: Information Sheet
Introduction
I am Peter Stampfel, a Physician Associate student at the Yale School of
Medicine. My team and I are doing research on a disease called intracranial aneurysms
which can cause bleeding inside a person’s brain. We are inviting you to participate in
our research because you have been found to have this disease but have decided with
your doctor to not have surgery. We are planning to invite nearly 300 people like you to
study this bleeding disease.
Please read this form to help you decide if you would like to participate in our
study. You do not have to decide today, so please take your time. There may be some
medical words or concepts that are foreign to you so please let us know if you have any
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confusion or would like to ask any questions either now or later. You are allowed to talk
about this study with anyone you choose to help you decide.
Purpose of the research
Intracranial aneurysms are a common problem in the blood vessels of the brain.
Sometimes these aneurysms rupture, much like a balloon, causing bleeding inside of
the head. The problem we have is that only some of these balloons pop, and we are not
very good at knowing when or why they do so. Taking pictures of the brain can help us
know when they may pop, but we are hoping to learn about a blood test that will also
help us know. This research is going to help us see if our blood test will help us keep
people with the disease from having this brain bleeding.
Type of Research Intervention
This research will involve asking you a few questions, doing a brief physical
exam, and taking a small amount of your blood from your arm once and testing it in a
laboratory. One year later we will take a picture of your brain to see how your aneurysm
is doing as well as ask you questions to see if anything has changed for you. Your
doctor may have told you that taking pictures of your brain over time is a normal part of
how they would take care of you anyway. This study will only add a few extra questions
and a blood test to the normal way we take care of aneurysms.
Participant selection
We are inviting all adults with an intracranial aneurysm that has been found
within the past 3 years in the Yale New Haven Health care system and who have not
had surgery to fix it to participate in our study. You have been invited because you have
at least one intracranial aneurysm that was found in the last three years and have
decided to not have surgery to fix it. You have been identified using your electronic
medical record.
Voluntary Participation
Your participation in this study is completely voluntary. We cannot and are not
forcing you to participate, it is your choice. You are allowed to change your mind and
stop participating later even if you have already agreed. Whether you chose to
participate or not will not affect your normal care with your normal doctor. If you choose
to participate, you will still be offered the normal treatment for intracranial aneurysms
that is routinely offered in the Yale New Haven Health system. We will tell you more
about this treatment later.
A. Procedures and Protocol
You will receive the normal treatment for your condition according to the
decisions that you and your doctor make. Often these are made by following national or
institutional recommendations. Treatment is either to have surgery to fix the aneurysm
or to watch and wait to see if it gets worse before having surgery. Often aneurysms will
not get so bad as to need surgery, but sometimes they do. This means that if your
aneurysm starts to cause you new problems, such as headaches or vision changes, you
will likely receive a picture of your brain. If the picture shows that the aneurysm may
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begin bleeding, you will be offered the option to have surgery to fix it. If the picture does
not show any of the bad warning signs, you will not get surgery, but your other problems
will still be treated normally. Sometimes an aneurysm begins to bleed without warning.
These can be deadly, and all efforts will be made to help make sure you are alright.
An important part of our research is a small blood test. We will take blood from
your arm using a needle and place it in a test tube. We will have to do this once. We will
take about two spoonsful of blood for our tests. If there is any leftover blood at the end
of our research we will destroy it and not let anyone else use it.
B. Description of the Process
- You will make two visits to the clinic during the research
- A small amount of blood will be taken from your arm during the first visit. This
blood will be sent to a laboratory to see how much of a particular substance is in
it normally. We will also ask you a few questions about how your health is and
take a few measurements such as your blood pressure and your weight.
- One year later we will take a picture of your brain in the same way your doctor
has been doing. Then we will compare the new picture to your old pictures to see
if anything has changed. We will also ask you some questions and repeat
measurements like blood pressure and your weight to see if anything has
changed.
Duration
This research takes place over 18 months or one and a half years. The first 6
months will be spent recruiting subjects like yourself to join our study. After this, you will
be asked to come to the clinic a total of 2 times. The first visit will include a blood
collection and a physical exam. Then a year later we will take a picture of your brain. At
the end of that time our research will be finished.
Side Effects
You may have a few side effects during the study. We will need to use a needle
to get your blood to test and the pinch from the needle can be uncomfortable. Some
people are very afraid of needles and sometimes can pass out. The needle can
sometimes cause bleeding in your arm that may hurt, or rarely cause an infection. To
help avoid an infection we will always use a new needle and clean your skin. Some
people are allergic to our skin cleaner and may have a reaction. If this is the case we
will use a different cleaner. We will do everything we can to make sure this does not
happen and will watch you closely to keep track of any bad effects. If any of these side
effects occur we will discuss it together with you to help decide if certain medications
can help fix the problem.
Risks
There is the risk that your aneurysm will get worse during the study. If this
happens your doctor will be told, and you and your loved ones will be able to talk with
them to help you decide what to do. This study will not keep you from getting any
treatment you may need. Also, while we will make every effort to protect your personal
information, there is a risk of this occurring.
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Benefits
Your participation in our study will help us gain knowledge about aneurysms. In
the future, this information can be used to help people with this disease, to keep them
from bleeding, and to help doctors know when they should have surgery. Because
intracranial aneurysms are common throughout the world, your participation may help
save lives in the future. Many aneurysms also run in families and your participation may
even help one of your loved ones.
Reimbursements
There will be no costs to you for participation in the study. Your blood tests and
imaging will be paid for by our funding. There are no reimbursements for participation.
Confidentiality
The information that we collect from this research project will be kept confidential
and only disclosed if required by the law. Information about you that will be collected
during the research will be put away and no-one but the researchers and the research
supervisors at Yale University institutions. These people are also required to keep all your
information confidential. Any information about you will have a number on it instead of
your name. Only the researchers will know what your number is, and that information will
be locked away. None of your personal information will be included without your
permission when the research is published.
We will help protect your information by only accessing it on university approved
and secured electronic devices. Any physical papers that we collect will be locked in a
cabinet in my locked office.
Sharing the Results
The knowledge that we get from this study will be shared with you after the study
is complete and before the results are published. If we have any reason to think that you
are at any increased risk of brain bleeding we will tell you immediately.
Right to Refuse or Withdraw
It is your choice to participate in this study. It is also your choice to change your
mind if you wish to not complete the study at any time. If you choose to not complete the
study you will not be allowed to rejoin again.
Alternatives to Participating
If you do not want to take part in this study you will be provided with the care that
you have agreed upon with your doctor.
Who to Contact
If you have any questions you may ask them now or later. If you wish to ask
questions later you may contact the Principal Investigator at his office: Peter Stampfel,
555-555-5555 or peterstampfel@fakeemail.com
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If you have any questions about your privacy rights, please contact the Yale Privacy
Officer at 444-444-4444.
This proposal has been reviewed and approved by the Yale Institutional Review Board,
which is a committee whose task it is to make sure that research participants are
protected from harm. If you have any complaints about this research or questions about
your rights as a participant, please contact the Yale Institutional Review Boards at 333333-3333 or email hrpp@yale.edu.

PART II: Certificate of Consent
I have read, or someone has read to me, the information in this document. I have
had the opportunity to ask questions about it and any questions that I have asked have
been answered to my satisfaction. By signing this form, I consent voluntarily to
participate as a participant in this research. By refusing to sign I understand that I will
not be able to participate in this research in the future. My signature also indicates that I
have received a copy of this document.
Print Name of Participant__________________
Signature of Participant ___________________
Date ___________________________
Day/month/year

If illiterate:
I have witnessed the accurate reading of the consent form to the potential participant,
and the individual has had the opportunity to ask questions. I confirm that the individual
has given consent freely.
Print name of witness_____________________

AND

Thumb print of

participant
Signature of witness ______________________
Date ________________________
Day/month/year

Statement by the researcher/person taking consent

I have accurately read out the information sheet to the potential participant, and to
the best of my ability made sure that the participant understands that the following will
be done:
1. Health Information will be gathered
2. Blood will be collected
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3. Repeat imaging will be completed at a later date
4. Their information will be protected in accordance with standard practice
5. They can withdraw from the study at any point and are choosing to participate by
their own choosing
I confirm that the participant was given an opportunity to ask questions about the
study, and all the questions asked by the participant have been answered correctly and
to the best of my ability. I confirm that the individual has not been coerced into giving
consent, and the consent has been given freely and voluntarily.
A copy of this ICF has been provided to the participant.
Print Name of Researcher/person taking the consent________________________

Signature of Researcher /person taking the consent__________________________
Date ___________________________
Day/month/year
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Appendix C: Sample Size Calculation
Our Sample size was based on a calculation program assuming a normal
distribution for MMP levels and a two tailed hypothesis. This program was cross
referenced using the UCSF Sample Size calculator to compare dichotomous outcomes
using the Chi-square statistic. Our calculated sample size of 256 subjects was
expanded by 10% (26 subjects) to a total of 282 subjects to account for expected loss to
follow up. Specific parameters of the calculation are listed below:
Alpha = 0.05
Beta = 0.20
Power = 0.80
Effect size = 10%
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